The purpose of the volume will be to set a basis for effective translational research. By inviting experts in the field of translational stroke research, each chapter will specifically address one or more components of preclinical stroke research. The emphasis will be placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.
The purpose of the volume will be to set a basis for effective translational research. By inviting experts in the field of translational stroke research, each chapter will specifically address one or more components of preclinical stroke research. The emphasis will be placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Vascular Targets For Ischemic Stroke Treatment.- Identifying Vascular Targets to Treat Hemorrhagic Stroke.- Experimental Platforms For Assessing White Matter Pathophysiology In Stroke.- Neuroprotection in Stroke.- Protein Aggregation And Multiple Organelle Damage After Brain Ischemia.- Antioxidants And Stroke. Success And Pitfalls.- Caspase-Independent Stroke Targets.- Hypoxia-Inducible Factor: A New Hope To Counteract Stroke.- Thrombin in Ischemic Stroke Targeting.- Toll-Like Receptor Agonists As Antecedent Therapy For Ischemic Brain Injury: Advancing Preclinical Studies To The Nonhuman Primate.- Angiogenesis and Arteriogenesis As Stroke Targets.- Hematopoietic Growth Factor Family For Stroke Drug Development.- Soluble Epoxide Hydrolase As A Stroke Target.- Membrane Potential As Stroke Target.- Hypothermia To Identify Therapeutic Targets For Stroke Treatment.- Stroke Preconditioning To Identify Endogenous Protective Or Regenerative Mechanisms.- MicroRNAs in Ischemic Brain: The Fine-tuning Specialists and Novel Therapeutic Targets.- Neuroglobin: A Novel Target For Endogenous Neuroprotection.- Characterization Of Novel Neuroprotective Lipid Analogues For The Treatment Of Stroke.- Na+/H+ Exchangers As Therapeutic Targets For Cerebral Ischemia.- Iron as a therapeutic target in intracerebral hemorrhage: Preclinical testing of deferoxamine.- Overcoming Barriers To Translation From Experimental Stroke Models. Animal Models Of Stroke For Preclinical Drug Development: A Comparative Study Of Flavonols For Cytoprotection.- Clinical Relevance In A Translational Rodent Model Of Acute Ischemic Stroke: Incorporating The Biological Variability Of Spontaneous Recanalization.- A Clinically Relevant Rabbit Embolic Stroke Model For Acute Ischemic Stroke Therapy Development: Mechanisms & Targets.- Animal Models of Intracranial Aneurysm for treatment.- Animal Models of SAH and Their Translation toClinical SAH.- ADME (Absorption, Distribution, Metabolism, Excretion) - The Real Meaning - Avoiding Disaster and Maintaining Efficacy for Preclinical Candidates.- CeeTox Analysis to De-risk Drug Development: The Three Antioxidants (NXY-059, RADICUT and STAZN).- Site-Specific, Sustained-Release Drug Delivery for Subarachnoid Hemorrhage.- Therapeutic Potential of Intranasal Delivery of Drugs and Cells for Stroke and other Neurological Diseases.- High-Dose Albumin For Neuroprotection In Acute Ischemic Stroke: From Basic Investigations To Multicenter Clinical Trial.- The Translation Procedure Of Low-Level Laser Therapy In Acute Ischemic Stroke- A Non-Pharmaceutics Noninvasive Method.- Use Of Microbubbles In Acute Stroke.- Combination of High-Intensity Focused Ultrasound and Microbubbles for Stroke Treatment.- Cellular Therapy for Ischemic Stroke.- Clinical Trial Design and Repair-Based Therapies after Stroke.- A Critical Review of Stroke Trial Analytical Methodology: Outcome Measures, Study Design and Correction for Imbalances.- Metabolic Imaging in Translational Stroke Research.- Computational Analysis: A bridge to translational stroke treatment.- Innovations in stroke clinical trial design.
Vascular Targets For Ischemic Stroke Treatment.- Identifying Vascular Targets to Treat Hemorrhagic Stroke.- Experimental Platforms For Assessing White Matter Pathophysiology In Stroke.- Neuroprotection in Stroke.- Protein Aggregation And Multiple Organelle Damage After Brain Ischemia.- Antioxidants And Stroke. Success And Pitfalls.- Caspase-Independent Stroke Targets.- Hypoxia-Inducible Factor: A New Hope To Counteract Stroke.- Thrombin in Ischemic Stroke Targeting.- Toll-Like Receptor Agonists As Antecedent Therapy For Ischemic Brain Injury: Advancing Preclinical Studies To The Nonhuman Primate.- Angiogenesis and Arteriogenesis As Stroke Targets.- Hematopoietic Growth Factor Family For Stroke Drug Development.- Soluble Epoxide Hydrolase As A Stroke Target.- Membrane Potential As Stroke Target.- Hypothermia To Identify Therapeutic Targets For Stroke Treatment.- Stroke Preconditioning To Identify Endogenous Protective Or Regenerative Mechanisms.- MicroRNAs in Ischemic Brain: The Fine-tuning Specialists and Novel Therapeutic Targets.- Neuroglobin: A Novel Target For Endogenous Neuroprotection.- Characterization Of Novel Neuroprotective Lipid Analogues For The Treatment Of Stroke.- Na+/H+ Exchangers As Therapeutic Targets For Cerebral Ischemia.- Iron as a therapeutic target in intracerebral hemorrhage: Preclinical testing of deferoxamine.- Overcoming Barriers To Translation From Experimental Stroke Models. Animal Models Of Stroke For Preclinical Drug Development: A Comparative Study Of Flavonols For Cytoprotection.- Clinical Relevance In A Translational Rodent Model Of Acute Ischemic Stroke: Incorporating The Biological Variability Of Spontaneous Recanalization.- A Clinically Relevant Rabbit Embolic Stroke Model For Acute Ischemic Stroke Therapy Development: Mechanisms & Targets.- Animal Models of Intracranial Aneurysm for treatment.- Animal Models of SAH and Their Translation toClinical SAH.- ADME (Absorption, Distribution, Metabolism, Excretion) - The Real Meaning - Avoiding Disaster and Maintaining Efficacy for Preclinical Candidates.- CeeTox Analysis to De-risk Drug Development: The Three Antioxidants (NXY-059, RADICUT and STAZN).- Site-Specific, Sustained-Release Drug Delivery for Subarachnoid Hemorrhage.- Therapeutic Potential of Intranasal Delivery of Drugs and Cells for Stroke and other Neurological Diseases.- High-Dose Albumin For Neuroprotection In Acute Ischemic Stroke: From Basic Investigations To Multicenter Clinical Trial.- The Translation Procedure Of Low-Level Laser Therapy In Acute Ischemic Stroke- A Non-Pharmaceutics Noninvasive Method.- Use Of Microbubbles In Acute Stroke.- Combination of High-Intensity Focused Ultrasound and Microbubbles for Stroke Treatment.- Cellular Therapy for Ischemic Stroke.- Clinical Trial Design and Repair-Based Therapies after Stroke.- A Critical Review of Stroke Trial Analytical Methodology: Outcome Measures, Study Design and Correction for Imbalances.- Metabolic Imaging in Translational Stroke Research.- Computational Analysis: A bridge to translational stroke treatment.- Innovations in stroke clinical trial design.
Rezensionen
From the reviews: "In Translational Stroke Research, Lapchak and Zhang have gathered an impressive, and very large, assortment of clinicians and researchers from around the world to offer reports of their studies, new ideas ... and directions for future research based mainly on pleotropic and combined therapies. ... The authors are to be congratulated on a great effort in furthering the available information and pitfalls in this field and pointing researchers and practitioners in a clinically significant direction. ... It makes for fascinating reading!" (Elizabeth A. M. Frost, Journal of Neurosurgical Anesthesiology, Vol. 24 (4), October, 2012)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
